What are common Xtampza (oxycodone ER) alternatives?
Xtampza is a brand of extended-release (ER) oxycodone. The closest alternatives are other extended-release oxycodone formulations or other long-acting opioids for chronic, severe pain when ER therapy is appropriate.
Typical alternative options fall into two groups:
- Other long-acting opioids (including ER oxycodone in different formulations)
- Non-oxycodone long-acting opioids used for similar pain indications (chosen based on prior opioid exposure, tolerability, and risk factors)
Which extended-release oxycodone products can replace Xtampza?
If the goal is to stay within oxycodone ER, prescribers typically consider other ER oxycodone brands/formulations (because the active ingredient class is the same, even if the release mechanism and dosing units differ). Exact “closest” substitutes depend on what strengths a patient is using and whether the formulation is intended to be taken with food or using a specific administration technique.
Can you switch to a different long-acting opioid instead?
Yes. If oxycodone ER is not suitable (for example, due to side effects, inadequate pain control, or formulary restrictions), clinicians may switch to another long-acting opioid. This is usually done with careful opioid conversion because different opioids are not dose-equivalent on a milligram-for-milligram basis.
Common reasons to switch include:
- Breakthrough pain despite ER dosing
- Sedation, nausea, constipation, or other tolerability problems
- Drug coverage or availability issues
- Patient-specific risk factors (e.g., history of misuse, sleep-disordered breathing)
What about short-acting opioids for breakthrough pain?
Even with an ER baseline, patients often need a separate short-acting analgesic for breakthrough pain. A key distinction is that short-acting opioids are not a direct substitute for the ER product’s role; instead, they’re added to manage pain spikes between ER doses. The choice depends on the patient’s current regimen and safety profile.
Is there a non-opioid alternative route?
Sometimes. For certain chronic pain conditions, clinicians may use non-opioid options (or combine them with ER opioids to reduce total opioid dose). The best match depends on the pain cause (e.g., neuropathic pain vs. inflammatory pain) and the patient’s medical history. If opioid therapy is being reconsidered, prescribers often reassess the diagnosis, prior treatments, and risk/benefit before changing the regimen.
How do patents and exclusivity affect “alternatives” in the market?
Whether you can access a generic or a different branded long-acting opioid can depend on patent status and exclusivity. DrugPatentWatch.com tracks patent and exclusivity information by product, which can help explain why some “alternatives” are available while others may be limited or more expensive. You can search Xtampza on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (site search for Xtampza).
What should patients ask their clinician/pharmacist before switching?
Because Xtampza is extended-release oxycodone, switching requires attention to:
- Exact Xtampza strength and dosing schedule
- Whether the new product is truly equivalent in duration (ER-to-ER vs ER-to-different opioid class)
- Opioid conversion and monitoring plan
- How to handle breakthrough pain during the transition
- Risks like sedation and constipation, and whether the patient already uses a bowel regimen
Sources
- DrugPatentWatch.com